Blood lead levels, ALAD gene polymorphisms, and mortality

Epidemiology

Volumn 22, Issue 2, 2011, Pages 273-278

  Van Bemmel, Dana M ^a   Li, Yan ^a,b   McLean, Jody ^c   Chang, Man Huei ^d   Dowling, Nicole F ^d   Graubard, Barry ^a   Rajaraman, Preetha ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS AT ARLINGTON   (United States)

^c NATIONAL CENTER FOR HEALTH STATISTICS   (United States)

^d NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PORPHOBILINOGEN SYNTHASE;

ADULT; ARTICLE; CANCER MORTALITY; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; HUMAN; LEAD BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

5-AMINOLEVULINATE SYNTHETASE; CARDIOVASCULAR DISEASES; CAUSALITY; FEMALE; HUMANS; LEAD; MALE; MIDDLE AGED; MORTALITY; NEOPLASMS; NUTRITION SURVEYS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS;

EID: 79951563373     PISSN: 10443983     EISSN: None     Source Type: Journal    
DOI: 10.1097/EDE.0b013e3182093f75     Document Type: Article

References (51)

1. Agency for Toxic Substances and Disease Registry. Toxicological Profile for Lead. Atlanta, GA: Services DoHaH; 2007.
2. US Environmental Protection A. Lead Compounds. Research Triangle, NC: Agency USEP; 2000.
3. Goyer RA. Lead toxicity: from overt to subclinical to subtle health effects. Environ Health Perspect. 1990;86:177-181.
4. Needleman HL. Low level lead exposure: a continuing problem. Pediatr Ann. 1990;19:208-214.
5. Pirkle JL, Schwartz J, Landis JR, Harlan WR. The relationship between blood lead levels and blood pressure and its cardiovascular risk implications. Am J Epidemiol. 1985;121:246-258. (Pubitemid 15158536)
6. IARC. IARC monographs on the evaluation of carcinogenic risks to humans: In: Organic and Organic Lead Compounds. Vol 87. Lyons, France: International Agency for Research on Cancer; 2004.
7. World Health Organization. International Classification of Diseases for Oncology. 2nd ed. Geneva: World Health Organization; 1990.
8. Claudio L, Lee T, Wolff MS, Wetmur JG. A murine model of genetic susceptibility to lead bioaccumulation. Fundam Appl Toxicol. 1997;35: 84-90.
9. Onalaja AO, Claudio L. Genetic susceptibility to lead poisoning. Environ Health Perspect. 2000;108(suppl 1):23-28. (Pubitemid 30168693)
10. Wetmur JG, Kaya AH, Plewinska M, Desnick RJ. Molecular characterization of the human delta-aminolevulinate dehydratase 2 (ALAD2) allele: implications for molecular screening of individuals for genetic susceptibility to lead poisoning. Am J Hum Genet. 1991;49:757-763. (Pubitemid 21891722)
11. Goering PL, Fowler BA. Regulatory roles of high-affinity metal-binding proteins in mediating lead effects on delta-aminolevulinic acid dehy-dratase. Ann NY Acad Sci. 1987;514:235-247. (Pubitemid 18097974)
12. Ziemsen B, Angerer J, Lehnert G, Benkmann HG, Goedde HW. Polymorphism of delta-aminolevulinic acid dehydratase in lead-exposed workers. Int Arch Occup Environ Health. 1986;58:245-247. (Pubitemid 16041086)
13. Wetmur JG, Lehnert G, Desnick RJ. The delta-aminolevulinate dehy-dratase polymorphism: higher blood lead levels in lead workers and environmentally exposed children with the 1-2 and 2-2 isozymes. Environ Res. 1991;56:109-119.
14. Zhao Y, Wang L, Shen HB, Wang ZX, Wei QY, Chen F. Association between delta-aminolevulinic acid dehydratase (ALAD) polymorphism and blood lead levels: a meta-regression analysis. J Toxicol Environ Health A. 2007;70:1986-1994. (Pubitemid 350034918)
15. Scinicariello F, Murray HE, Moffett DB, Abadin HG, Sexton MJ, Fowler BA. Lead and delta-aminolevulinic acid dehydratase polymorphism: where does it lead? A meta-analysis. Environ Health Perspect. 2007;115:35-41. (Pubitemid 46050279)
16. Jemal A, Graubard BI, Devesa SS, Flegal KM. The association of blood lead level and cancer mortality among whites in the United States. Environ Health Perspect. 2002;110:325-329. (Pubitemid 34308594)
17. Lustberg M, Silbergeld E. Blood lead levels and mortality. Arch Intern Med. 2002;162:2443-2449. (Pubitemid 35340460)
18. Schober SE, Mirel LB, Graubard BI, Brody DJ, Flegal KM. Blood lead levels and death from all causes, cardiovascular disease, and cancer: results from the NHANES III mortality study. Environ Health Perspect. 2006;114:1538-1541. (Pubitemid 44509651)
19. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey. Atlanta, GA: Centers for Disease Control and Prevention; 2007.
20. National Center for Health Statistics, CDC, Third National Health and Nutrition Examination Survey (NHANESIII) data files 2007. Available at http://www.cdc.gov/nchs/nhanes.htm. Accessed June 2009.
21. Centers for Disease Control and Prevention. Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-1994. Vital Health Stat 1994;32:1-407.
22. National Center for Health Statistics CDC, NHANES III genetic data 2009 Available at http://www.cdc.gov/nchs/nhanes/genetics/genetic.htm. Accessed August 25, 2009.
23. Chang MH, Lindegren ML, Butler MA, et al. Prevalence in the United States of selected candidate gene variants: third National Health and Nutrition Examination Survey, 1991-1994. Am J Epidemiol. 2009;169: 54-66.
24. National Center for Health Statistics. Plan and Operation of the Third National Health and Nutrition Examination Survey, 1988-1994. Hyatts-ville, MD: National Center for Health Statistics; 1994. Vital and Health Statistics, Series 1: Programs and Collections Procedures, no 32.
25. Centers for Disease Control and Prevention. NHANES Genetic Data. National Center for Health Statistics. Hyattsville, MD: National Center for Health Statistics; 2009.
26. Pirkle JL, Brody DJ, Gunter EW, et al. The decline in blood lead levels in the United States. The National Health and Nutrition Examination Surveys (NHANES). JAMA. 1994;272:284-291.
27. National Center for Health Statistics. Office of Analysis and Epidemiology. The Third National Health and Nutrition Survey (NHANES III) Linked Mortality File, Mortality Follow-up Through 2006: Matching Methodology. Hyattsville, MD: National Center for Health Statistics; 2009. Available at http://www.cdc.gov/nchs/data/datalinkage/matching-methodology-nhanes3-final.pdf
28. Perlstein TS, Weuve J, Pfeffer MA, Beckman JA. Red blood cell distribution width and mortality risk in a community-based prospective cohort. Arch Intern Med. 2009;169:588-594.
29. Ruhl CE, Everhart JE. Elevated serum alanine aminotransferase and gamma-glutamyl transferase and mortality in the United States population. Gastroenterology. 2009;136:477.e11-485.e11.
30. Centers for Disease Control and Prevention DHHS. Interpreting and managing blood lead levels <10/ng/dL in children and reducing childhood exposures to lead: recommendations of CDC's advisory committee on childhood lead poisoning prevention. MMWR Recomm Rep. 2007; 56(RR-8) 1-16.
31. Li Y, Graubard BI. Testing Hardy-Weinberg equilibrium and homogeneity of Hardy-Weinberg disequilibrium using complex survey data. Biometrics. 2009;65:1096-1104.
32. Korn EL, Graubard BI, Midthune D. Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol. 1997;145:72-80. (Pubitemid 27009060)
33. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med. 1989;8:551-561. (Pubitemid 19116001)
34. Korn EL, Graubard BI. Analysis of Health Surveys. Wiley Series in Probability and Statistics. New York: John Wiley and Sons; 1999.
35. Schwartz BS, Lee BK, Stewart W, Ahn KD, Springer K, Kelsey K. Associations of delta-aminolevulinic acid dehydratase genotype with plant, exposure duration, and blood lead and zinc protoporphyrin levels in Korean lead workers. Am J Epidemiol. 1995;142:738-745.
36. Bergdahl IA, Grubb A, Schutz A, et al. Lead binding to delta-aminole-vulinic acid dehydratase (ALAD) in human erythrocytes. Pharmacol Toxicol. 1997;81:153-158. (Pubitemid 27432568)
37. Fleming DE, Chettle DR, Wetmur JG, et al. Effect of the delta-aminolevulinate dehydratase polymorphism on the accumulation of lead in bone and blood in lead smelter workers. Environ Res. 1998;77:49-61. (Pubitemid 28223875)
38. Rajaraman P, Stewart PA, Samet JM, et al. Lead, genetic susceptibility, and risk of adult brain tumors. Cancer Epidemiol Biomarkers Prev. 2006;15:2514-2520. (Pubitemid 46048314)
39. Rajaraman P, Schwartz BS, Rothman N, et al. Delta-aminolevulinic acid dehydratase polymorphism and risk of brain tumors in adults. Environ Health Perspect. 2005;113:1209-1211. (Pubitemid 41387661)
40. Bellinger D, Hu H, Titlebaum L, Needleman HL. Attentional correlates of dentin and bone lead levels in adolescents. Arch Environ Health. 1994;49:98-105. (Pubitemid 24109073)
41. Petrucci R, Leonardi A, Battistuzzi G. The genetic polymorphism of delta-aminolevulinate dehydratase in Italy. Hum Genet. 1982;60:289-290. (Pubitemid 12120548)
42. Battistuzzi G, Petrucci R, Silvagni L, Urbani FR, Caiola S. delta-Aminolevulinate dehydratase: a new genetic polymorphism in man. Ann Hum Genet. 1981;45(pt 3):223-229. (Pubitemid 11051340)
43. Guo GG, Gu M, Etlinger JD. 240-kDa proteasome inhibitor (CF-2) is identical to delta-aminolevulinic acid dehydratase. J Biol Chem. 1994; 269:12399-12402. (Pubitemid 24202014)
44. Grunberg-Etkovitz N, Greenbaum L, Grinblat B, Malik Z. Proteasomal degradation regulates expression of porphobilinogen deaminase (PBGD) mutants of acute intermittent porphyria. Biochim Biophys Acta. 2006; 1762:819-827. (Pubitemid 44403049)
45. Pischik E, Kauppinen R. Neurological manifestations of acute intermittent porphyria. Cell Mol Biol (Noisy-le-grand). 2009;55:72-83.
46. Teixeira PC, Onuki J, Medeiros MH, Dornemann D, Di Mascio P. DNA damage by 3,6-dihydropyrazine-2,5-dipropanoic acid, the cyclic dimer-ization product of 5-aminolevulinic acid. Biol Chem. 2001;382:913-918. (Pubitemid 32677366)
47. Onuki J, Rech CM, Medeiros MH, de A Umbuzeiro G, Di Mascio P. Genotoxicity of 5-aminolevulinic and 4,5-dioxovaleric acids in the salmonella/microsuspension mutagenicity assay and SOS chromotest. Environ Mol Mutagen. 2002;40:63-70. (Pubitemid 34848040)
48. Warren MJ, Cooper JB, Wood SP, Shoolingin-Jordan PM. Lead poisoning, haem synthesis and 5-aminolaevulinic acid dehydratase. Trends Biochem Sci. 1998;23:217-221. (Pubitemid 28302619)
49. Rabinowitz MB, Wetherill GW, Kopple JD. Kinetic analysis of lead metabolism in healthy humans. J Clin Invest. 1976;58:260-270.
50. Rabinowitz MB. Toxicokinetics of bone lead. Environ Health Perspect. 1991;91:33-37.
51. Smith DR, Osterloh JD, Flegal AR. Use of endogenous, stable lead isotopes to determine release of lead from the skeleton. Environ Health Perspect. 1996;104:60-66. (Pubitemid 26059445)